Compare

Sensei Biotherapeutics/$FTH

1D1W1M3M6MYTD1Y5YMAX

About Sensei Biotherapeutics

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
Ticker
$FTH
Sector
Health
Primary listing
NASDAQ
Employees
29
Headquarters
Rockville, United States
Website
www.faeththerapeutics.com

FTH Metrics

BasicAdvanced
$345M
-
-$24.64
-
-

What the Analysts think about FTH

Analyst ratings (Buy, Hold, Sell) for Sensei Biotherapeutics stock.
Analyst projections of the future price of Sensei Biotherapeutics stock.

Bulls say / Bears say

PIK-201 produced a 33% confirmed response rate and estimated median progression-free survival of 7.4 months in previously treated endometrial cancer; the confirmed response rate was 44% among patients with PIK3CA mutations. This is an encouraging preliminary signal in a difficult-to-treat setting. (Faeth Therapeutics)
The FDA granted Fast Track status to PIKTOR with paclitaxel for biomarker-selected advanced endometrial cancer, and Faeth says the Phase 2 results support moving towards a Phase 3 trial, subject to regulatory alignment. This could help the company advance its lead programme more quickly. (Faeth Therapeutics, Faeth Therapeutics)
PIKTOR offers a second potential market in HR+/HER2-negative breast cancer. Faeth reported tumour-growth inhibition in mouse models, including in combination with fulvestrant and palbociclib, and its Phase 1b/2 trial is under way with interim data expected in 2027. (Faeth Therapeutics, Faeth Therapeutics)
The efficacy result comes from a small, open-label, single-arm Phase 2 trial, so it cannot establish that PIKTOR caused the responses or performs better than other treatments. Six of 42 treated patients stopped before their first response scan, adding uncertainty to the early data. (Faeth Therapeutics)
Treatment-related toxicity was material: 64% of patients had a Grade 3 or worse event, including severe neutropenia in 26%. Although only 5% stopped treatment because of treatment-related events, tolerability remains a risk as development expands. (Faeth Therapeutics)
The share count rose sharply, from about 1.26 million at the end of 2025 to 25.84 million at September 2026, diluting existing holders. The latest filing also lists millions of outstanding options and other potentially dilutive securities. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.

FTH Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

FTH Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

FTH News

AllArticlesVideos

Faeth Therapeutics to Participate in Upcoming November Investor Conferences

Business Wire1 day ago

Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026

Business Wire6 days ago

Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates

Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.